{
    "Clinical Trial ID": "NCT00764322",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ultra-rapid Metabolizers",
        "  Those with the highest transformation of the CYP2D6 genotype to allelic activity",
        "INTERVENTION 2: ",
        "  Extensive Metabolizers",
        "  Those with the most normal transformation of the CYP2D6 genotype to allelic activity"
    ],
    "Eligibility": [
        "Inclusion:",
        "  Histologically confirmed invasive carcinoma of the breast or ductal breast carcinoma in situ Has been receiving tamoxifen citrate at a dose of 20 mg/day for at least 4 months either for the treatment of invasive or non-invasive carcinoma of the breast or for breast cancer recurrence prevention",
        "  Expected duration of tamoxifen citrate treatment at least 6 months Hormone receptor status not specified Concurrent participation in non-treatment studies allowed provided it will not interfere with participation in this study Menopausal status not specified Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Life expectancy  6 months Absolute Neutrophil Count (ANC)  1.0 x 10^9/L Platelet count  100 x 10^9/L Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)  2.5 times Upper Limit of Normal (ULN) Total bilirubin  2.5 times ULN Creatinine clearance  50 mL/min Fertile patients must use effective contraception",
        "  PRIOR CONCURRENT THERAPY:",
        "  No limitations to number of prior therapies",
        "  No limitations for prior radiotherapy",
        "  More than 14 days since prior and no other concurrent investigational agent",
        "  Exclusion:",
        "  Not pregnant or nursing No active, serious infection or medical or psychiatric illness likely to preclude study participation No psychiatric conditions that would preclude study compliance or informed consent No history of venous thromboembolism, transient ischemic attack, or cerebral vascular accident No history of allergic reaction to tamoxifen citrate or any of its reagents No concurrent coumadin",
        "  No concurrent medications known to inhibit CYP2D6, including any of the following:",
        "  Amiodarone",
        "  Haloperidol",
        "  Indinavir",
        "  Ritonavir",
        "  Quinidine",
        "  No concurrent selective serotonin reuptake inhibitors, except the following:",
        "  Venlafaxine",
        "Citalopram"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes",
        "  Measurements of plasma concentrations of the key active metabolite of tamoxifen, endoxifen, were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM), extensive (EM), intermediate (IM) or poor (PM) metabolism. A given patient has two alleles, giving them 10 possible allelic combinations, or diplotypes (UM/UM, UM/EM, EM/EM, etc.). These diplotypes are collapsed into four phenotypes, UM, EM, IM or PM.",
        "  Time frame: 4 months",
        "Results 1: ",
        "  Arm/Group Title: Ultra-rapid Metabolizers",
        "  Arm/Group Description: Those with the highest transformation of the CYP2D6 genotype to allelic activity",
        "  Overall Number of Participants Analyzed: 5",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: ng/mL  Baseline endoxifen concentration: 5 participants",
        "  8.4         (4.59)",
        "  4-Month endoxifen concentration: 4 participants",
        "  15.35         (5.48)",
        "Results 2: ",
        "  Arm/Group Title: Extensive Metabolizers",
        "  Arm/Group Description: Those with the most normal transformation of the CYP2D6 genotype to allelic activity",
        "  Overall Number of Participants Analyzed: 119",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: ng/mL  Baseline endoxifen concentration: 119 participants",
        "  10.00         (6.00)",
        "  4-Month endoxifen concentration: 106 participants",
        "  9.30         (5.03)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/161 (0.00%)",
        "  headache * 20/161 (0.00%)",
        "  Mood alteration 2 [1]0/161 (0.00%)",
        "  Hemorrhage, GU 0/161 (0.00%)",
        "  thrombosis * 2 [2]0/161 (0.00%)",
        "Adverse Events 2:",
        "  Total: 3/290 (1.03%)",
        "  headache * 21/290 (0.34%)",
        "  Mood alteration 2 [1]1/290 (0.34%)",
        "  Hemorrhage, GU 1/290 (0.34%)",
        "  thrombosis * 2 [2]1/290 (0.34%)"
    ]
}